drugset / Trial / NCT00237237
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Timeline
- Start
- 2005-10
- Primary completion
- 2007-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vildagliptin | Other / unclassified | 100 mg | — |